









CLAIMS

1. A compound, or a pharmaceutically acceptable salt thereof, selected from the following formulae:



,

,

,

,

,

,

,

and




2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:




8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:



9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:



10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is shown in the following formula:



11. A pharmaceutical composition comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

12. An RORγ antagonist comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

13. An agent for use in treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic

disease, comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof.

14. The agent for use of claim 13, wherein the disease is autoimmune disease.

15. The agent for use of claim 14, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes, and graft versus host disease.

16. The agent for use of claim 13, wherein the disease is metabolic disease.

17. The agent for use of claim 16, wherein the metabolic disease is diabetes.

18. Use of the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.

19. The use according to claim 18, wherein the disease is autoimmune disease.

20. The use according to claim 19, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes, and graft versus host disease.

21. The use according to claim 18, wherein the disease is metabolic disease.

22. The use according to claim 21, wherein the metabolic disease is diabetes.

23. A compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use as an agent for treating or preventing a disease selected from the group consisting of autoimmune disease, allergic disease, dry eye, fibrosis, and metabolic disease.

24. The compound or the pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease is autoimmune disease.

25. The compound or the pharmaceutically acceptable salt thereof for use according to claim 24, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, uveitis, polymyalgia rheumatica, type I diabetes, and graft versus host disease.

26. The compound or the pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease is metabolic disease.

27. The compound or the pharmaceutically acceptable salt thereof for use according to claim 26, wherein the metabolic disease is diabetes.